GROWTH STAGE MEDICAL DEVICE COMPANY TREATING INTESTINAL TRANSIT DISORDERS WITH A

PURELY PHYSICAL, NON-DRUG, NON-INVASIVE SOLUTION.

“BEST OF EUROPEAN HEALTHCARE INNOVATIONS”

250 Million People in EU & USA

€100 Billion Annual Cost to Healthcare Systems

The Problem:

Chronic Constipation

Those who suffer the most

80% of Neurogenic Patients (SCI, MS, PD)

50% of Elderly People

Neurogenic Patients (SCI, MS, PD)

Elderly People

SIDE EFFECTS

Fecal Incontinence

Fecal Impaction

and many others…

Colorectal Cancer

Those who suffer the most

Pharmaceutical

Invasive

Where are our competitors? Opportunity gap

Price

Side Effects

~1000€/year

Laxatives ~2300€/year

Enemas

non-pharma non-invasive no-side-effects

Surgical Solutions

>35.000€

Liu et al. Journal of Neurology 2005

Ayaş et al. Am J Phys Med Rehabil. 2006

“Automated Abdominal Massage”

Automated Colon Specific Massage

ALGORITHM DEVELOPED IN COLLABORATION WITH

Non-pharma, non-invasive, no-side-effects

Lightweight Belt w/ pneumatic technology Our first product

connectivity and APP development in progress

2-3 per week

12

10

8

6

4

2

PRE-USE POST-USE

DAILY

BOWEL MOVEMENTS

treatment works! Positive clinical results

Herrero-Fresneda et al. EUGMS 2016

“METHOD AND APPARATUS FOR AUTOMATED ABDOMINAL MASSAGE

TO RELIEVE CONSTIPATION”

Protected Intellectual Property PCT/IB2015/001576

How big is this opportunity?

150M People

- 90B €

ADJACENT MARKETS Opioid-Induced Const. OTC-Health

TAM: EU & USA Neuro & Elderly 120 Million People 204 Billion €

SAM: EU Neurogenic Bowel 4 Million People 6.8 Billion €

TM: Germany Neurogenic Bowel 0.5 Million People 850 Million €

€ 850 M

€ 6.8 B

€ 204 B

Market Size

Multidisciplinary Experts The Founder Team

Marc CRMO

Immaculada CSO

Angel CTO

Markus CEO

MSc Product Design

PhD Telecom. Engineer

PhD Microbiology

PhD Biomed. Sciences

Multidisciplinary Experts The Founder Team

Marc CRMO

Immaculada CSO

Angel CTO

Markus CEO

+ Employees + Intl. Advisory Board + Medical KOL

Funding so far

raised € 2,6 Million so far

in private and public funds

17

Funding Needs Strategy

Working capital

33% 29% 16% 14% 8%

Clinical budgets

Marketing & Biz Dev

Regulatory and IP

General expenses

SERIES A – 2020 Focus: MAIN EU REIMBURSED MARKETS Funds deployed:

€ 1,630,000

SERIES B – 2022 Focus: US MARKET ENTRY OTC MARKET Funds deployed: € 5,000,000

Purely physical - non-pharma - non-invasive

Product developed & on the market CE & ISO certified IP protected Clinical proof Proof of business with first sales in ES, GER, UK & NL Distributor agreements & pipeline Private healthcare reimbursement Confirmed M&A interest by industry players Clear Roadmap Public healthcare reimbursement in Germany (mid 2020) & UK (early 2021)

✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔

Investment Highlights Milestones